189 related articles for article (PubMed ID: 33844437)
1. Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody.
Nakajima M; Guo HF; Hoseini SS; Suzuki M; Xu H; Cheung NV
Pediatr Blood Cancer; 2021 Jul; 68(7):e28971. PubMed ID: 33844437
[TBL] [Abstract][Full Text] [Related]
2. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
[TBL] [Abstract][Full Text] [Related]
3. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
4. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
Park JA; Santich BH; Xu H; Lum LG; Cheung NV
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986124
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
Park JA; Espinosa-Cotton M; Guo HF; Monette S; Cheung NV
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36990507
[TBL] [Abstract][Full Text] [Related]
6. Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.
Park JA; Wang L; Cheung NV
J Hematol Oncol; 2021 Sep; 14(1):142. PubMed ID: 34496935
[TBL] [Abstract][Full Text] [Related]
7. Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.
Park JA; Cheung NV
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086947
[TBL] [Abstract][Full Text] [Related]
8. Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors.
Cheng M; Santich BH; Xu H; Ahmed M; Huse M; Cheung NK
Oncoimmunology; 2016 Jun; 5(6):e1168557. PubMed ID: 27471647
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.
Hoseini SS; Dobrenkov K; Pankov D; Xu XL; Cheung NK
Oncoimmunology; 2017; 6(6):e1320625. PubMed ID: 28680755
[TBL] [Abstract][Full Text] [Related]
10. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
Cheng M; Ahmed M; Xu H; Cheung NK
Int J Cancer; 2015 Jan; 136(2):476-86. PubMed ID: 24895182
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex.
Cheal SM; Xu H; Guo HF; Zanzonico PB; Larson SM; Cheung NK
Mol Cancer Ther; 2014 Jul; 13(7):1803-12. PubMed ID: 24944121
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.
Yankelevich M; Kondadasula SV; Thakur A; Buck S; Cheung NK; Lum LG
Pediatr Blood Cancer; 2012 Dec; 59(7):1198-205. PubMed ID: 22707078
[TBL] [Abstract][Full Text] [Related]
13. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
14. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.
Wu Z; Guo HF; Xu H; Cheung NV
Mol Cancer Ther; 2018 Oct; 17(10):2164-2175. PubMed ID: 30082472
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG
Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495
[TBL] [Abstract][Full Text] [Related]
16. A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells.
Chen YJ; Chen M; Cheng TL; Tsai YS; Wang CH; Chen CY; Wu TY; Tzou SC; Wang KH; Cheng JJ; Kao AP; Lin SY; Chuang KH
J Biomed Sci; 2023 May; 30(1):35. PubMed ID: 37259079
[TBL] [Abstract][Full Text] [Related]
17. Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.
Lin TY; Park JA; Long A; Guo HF; Cheung NV
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34497115
[TBL] [Abstract][Full Text] [Related]
18. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.
Long AW; Xu H; Santich BH; Guo H; Hoseini SS; de Stanchina E; Cheung NV
J Hematol Oncol; 2024 Apr; 17(1):20. PubMed ID: 38650005
[TBL] [Abstract][Full Text] [Related]
19. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
[TBL] [Abstract][Full Text] [Related]
20. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.
Ahmed M; Cheng M; Cheung IY; Cheung NK
Oncoimmunology; 2015 Apr; 4(4):e989776. PubMed ID: 26137406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
